LifespanningRx adds RegenTherapy partnership for regenerative longevity programs

By AI, Created 4:32 PM UTC, May 18, 2026, /AGP/ – LifespanningRx and RegenTherapy announced a partnership on May 11, 2026, to integrate CellGen Factors into the longevity platform and expand access to regenerative medicine programs. The deal pairs LifespanningRx’s consumer reach with RegenTherapy’s clinical and fulfillment infrastructure as the companies prepare a public rollout in the coming months.

Why it matters: - The partnership expands LifespanningRx beyond general longevity offerings into regenerative medicine programs tied to cellular signaling, recovery, performance optimization, and healthy aging. - The deal aims to make advanced regenerative strategies more scalable and accessible through a consumer-facing platform. - The collaboration could broaden how longevity services are packaged, marketed, and delivered to consumers.

What happened: - LifespanningRx and RegenTherapy announced a strategic partnership on May 11, 2026, to integrate CellGen Factors into the LifespanningRx platform. - The companies said the integration will support regenerative longevity programs built around structured longevity protocols and advanced cell signaling technologies. - Jean Fallacara, founder of Lifespanning, described the partnership as a major expansion of the company’s platform. - Dr. Arvind Chakravarthy said the collaboration reflects a new era for regenerative medicine.

The details: - LifespanningRx is contributing its consumer-facing longevity platform, branding, and commercialization infrastructure. - RegenTherapy is providing clinical integration, regenerative medicine expertise, fulfillment operations, and therapeutic support systems. - RegenTherapy will handle the underlying operational and clinical infrastructure for CellGen Factors programs, including fulfillment, onboarding support, and regenerative integration systems. - CellGen Factors is being positioned as a regenerative optimization program designed to support the body’s natural communication and repair systems. - Each program is designed around progressive regenerative strategies tailored to different levels of optimization, recovery, and longevity support. - RegenTherapy leadership, including Dr. Arvind Chakravarthy and Sanjiv Lal, will serve as Cell Signaling Advisors to the platform and broader regenerative initiatives. - Initial fulfillment and operational support will run through RegenTherapy’s South Carolina distribution infrastructure. - LifespanningRx will lead brand rollout, memberships, commercialization strategy, customer experience, and platform expansion. - The companies are preparing coordinated launch initiatives, strategic partnerships, and educational campaigns for the public rollout in the coming months. - LifespanningRx describes itself as a longevity optimization platform focused on healthspan, performance, recovery, and biological resilience. - RegenTherapy describes itself as a regenerative medicine and clinical integration organization focused on therapeutic strategies, operational infrastructure, and regenerative optimization systems.

Between the lines: - The structure of the deal suggests a division of labor: LifespanningRx handles consumer growth, while RegenTherapy anchors the clinical and operational side. - The addition of advisors from RegenTherapy signals an effort to add medical credibility to a consumer longevity brand. - The emphasis on education and partnerships points to a phased rollout rather than an immediate broad launch.

What’s next: - The companies plan to launch CellGen Factors publicly in the coming months. - Coordinated marketing, education, and partnership efforts are expected ahead of rollout. - LifespanningRx and RegenTherapy will continue building the regenerative longevity programs and supporting infrastructure around the partnership.